Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271919 · ClinicalTrials.gov registry record · Phase 4
Varenicline and Combined NRT for Smoking Cessation
A Phase 4 study of Tobacco Use Disorder and Cigarette Smoker, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 4
- Development phase
- 631
- Enrollment target
- 1
- Study location
NCT02271919: Active Phase 4 study of Tobacco Use Disorder and Cigarette Smoker, sponsored by M.D. Anderson Cancer Center.
NCT02271919 is a Phase 4 study of Tobacco Use Disorder and Cigarette Smoker that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 631 participants, above the 230-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (174% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02271919, a Phase 4 study of Tobacco Use Disorder and Cigarette Smoker, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 631 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized pilot phase IV trial studies the side effects and how well varenicline works compared to nicotine replacement therapy in helping patients that smoke to quit. Varenicline is a drug that acts the same way as nicotine in the brain but is not habit-forming. Nicotine replacement therapy consists of nicotine patches and lozenges. It is not yet known if varenicline is more effective than nicotine replacement therapy in helping patients quit smoking.
Primary Outcome
7-day point-prevalence smoking abstinence (i.e., no self-reported smoking in the past 7 days), verified by expired carbon monoxide \<6 ppm (parts per millions)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Varenicline
- OTHER Tobacco Cessation Counseling
- DRUG Nicotine Patch
- DRUG Nicotine Lozenge
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 631 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
What the registry record for NCT02271919 still lists
NCT02271919 is an interventional study that assigns participants to a tested intervention. The registered 631 participants enrollment target is mid-sized for trials with a published cap, above the 230-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (174% higher).
The record links to 2 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02271919 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02271919 about?
NCT02271919 is a clinical study titled "Varenicline and Combined NRT for Smoking Cessation". This randomized pilot phase IV trial studies the side effects and how well varenicline works compared to nicotine replacement therapy in helping patients that smoke to quit. Varenicline is a drug that acts the same way as nicotine in the brain but is not habit-forming. Nicotine replacement therapy c...
What is the current status of trial NCT02271919?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 631 participants. The study started on 2015-05-14. Estimated completion is 2026-06-30.
What conditions does trial NCT02271919 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Cigarette Smoker.
What interventions are being tested in trial NCT02271919?
The interventions under investigation include: Placebo (OTHER), Varenicline (DRUG), Tobacco Cessation Counseling (OTHER), Nicotine Patch (DRUG), Nicotine Lozenge (DRUG).
Who is sponsoring clinical trial NCT02271919?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02271919 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02271919's enrollment target sits among peer trials
631 9th of 70 higher than 62 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beta-Adrenergic Modulation of Drug Cue Reactivity
RECRUITING · Phase 4
-
E-cigarette Cessation in Adults Who Co-use Cannabis
RECRUITING · Phase 4
-
Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
COMPLETED · Phase 4
-
A Comparison of Bupropion SR and Placebo for Smoking Cessation
COMPLETED · Phase 4
-
Varenicline Effects In Schizophrenic Smokers
COMPLETED · Phase 4
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05744973 · 631 participants
Multi-level Predictors of Structural Racism and Discrimination and Associations With Health and Well-being Across the Life Course in Diverse Families
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI